Showing posts with label Dilip Shanghvi. Show all posts
Showing posts with label Dilip Shanghvi. Show all posts

Wednesday, February 27, 2019

Mukesh Ambani world's 10th richest with networth of $54 bn: Hurun Report

Companies News:

With a networth of $54 billion, Reliance Industries Chairman Mukesh Ambani has broken into the global top 10 richest billionaire list complied by Hurun Research.

"The only Asian in the Top 10, Ambani's wealth is based on telecom, retail and energy, and bucked the poor stock market trend in India last year," Hurun Research said in a statement.
The Hurun Global Rich List 2019 is topped by Amazon chief Jeff Bezos for the second year in a row, while the senior Ambani is placed 10th with a network of Rs 3.83 trillion, thanks to a rally in RIL shares, which had topped the Rs 8-lakh-crore-mark last month. Ambani owns almost 52 percent in Reliance.

Anil Ambani, held in contempt of court by the Supreme Court last week for not paying up Ericsson Rs 540 crore, has lost over $5 billion, from $7 billion seven years ago to $1.9 billion this year, even though both the brothers got off with more or less same amount of inherited wealth.
"Having started off similarly after the break-up of the family wealth, Mukesh added $30 billion to his wealth in the past seven years, while Anil has lost over $5 billion during the same period," says the Hurun report.

Other individuals from India who were named in the list include S P Hinduja (40th), Azim Premji (57) and Cyrus Poonawalla.

Cyrus S Poonawalla, chairman of the Poonawalla group that run Serum Institute, with a networth of $13 billion is not only ranked as the fourth richest Indian but also breaks into the top 100 global ranking.


 Steel giant ArcelorMittal's Lakshmi Mittal stands at fifth position, followed by Kotak Mahindra's Uday Kotak ($11 billion), Gautam Adani ($9.9 billion) and Sun Pharma's Dilip Shanghvi ($9.5 billion)...Read More

Tuesday, January 22, 2019

Sun Pharma to settle Dubai firm loans, shift distribution arm to subsidiary

Companies News:

Seeking to ease investor concerns, embattled drug major Sun Pharmaceutical Industries on Tuesday announced plans to unwind loans of Rs 2,238 crore given to a Dubai-based company, Atlas Global Trading FZC, and transfer the distribution of the domestic formulation business to a subsidiary from a separate entity.

Sun Pharma said the company’s consolidated balance sheet had receivables of Rs 2,238 crore from a non-related party. “This liability was in respect of Atlas assuming the damages on account of Protonix patent litigation settlement entered by Sun Pharma, which was disclosed in Sun Pharma’s annual report for fiscal year 2014,” it said in a statement.

Last month, when investors had asked Sun Pharma Managing Director Dilip Shanghvi about the loan in a conference call, he said it was given to a “non-related” party, but did not give details.


 Responding to Business Standard queries, Sun Pharma clarified Atlas Global or any of its subsidiary was not a related party at any point in time...Read More